References
- Abbate A, Narula J. Role of Apoptosis in Adverse Ventricular Remodeling. Heart Fail. Clin. 2012;8:79-86.
- Moe GW, Marín-García J. Role of Cell Death in the Progression of Heart Failure. Heart Fail. Rev. 2016;21: 157-167.
- Guo X, Chen Y, Liu Q. Necroptosis in Heart Disease: Molecular Mechanisms and Therapeutic Implications. J. Mol. Cell Cardiol. 2022;169:74-83.
- Zhe-Wei S, Li-Sha G, Yue-Chun L. The Role of Necroptosis in Cardiovascular Disease. Front. Pharmacol. 2018;9:721.
- Piamsiri C, Maneechote C, Siri-Angkul N, Chattipakorn SC, Chattipakorn N. Targeting Necroptosis as Therapeutic Potential in Chronic Myocardial Infarction. J. Biomed. Sci. 2021;28:25.
- Simmonds SJ, Cuijpers I, Heymans S, et al. Cellular and molecular differences between HFpEF and HFrEF: a step ahead in an improved pathological understanding. Cells. 2020;9:242.
- van Heerebeek L, Borbely A, Niessen HW, et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 2006;113:1966-73.
- Czepluch FS, Wollnik B, Hasenfuß G. Genetic determinants of heart failure: facts and numbers. ESC Heart Failure 2018;5:211-7.
- Seravalle G, Quarti-Trevano F, Dell'Oro R, et al. Sympathetic and baroreflex alterations in congestive heart failure with preserved, midrange and reduced ejection fraction. J Hypertens. 2019;37:443-8.
- Schwinger RHG, Böhm M, Koch A, et al. The Failing Human Heart is unable to use the Frank-Starling Mechanism. Circ Res. 1994;74:959-69.
- Kehat I, Molkentin JD. Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation. 2010;122:2727-3.
- Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of beta-adrenergic signaling in heart failure? Circ Res. 2003 Nov 14;93(10):896-906. doi: 10.1161/01.RES.0000102042.83024.CA. PMID: 14615493.
- Böhm M, LaRosee K, Schwinger RHG, et al. Evidence for reduction of norepinephrine uptake sites in the failing human heart. J AmColl Cardiol. 1995;25:146-53.
- Goldsmith SR. The role of vasopressin in congestive heart failure. Cleve Clin JMed. 2006;73:S19-23.
- Urata H, Arakawa K. Angiotensin II-forming systems in cardiovascular diseases. Heart Failure Rev. 1998;3:119-24.
- Dendorfer A, Thornagel A, Raasch W, et al. Angiotensin II induces catecholamine release by direct ganglionic excitation. Hypertension 2002;40:348-54.
- Richards AM. The renin-angiotensin-aldosterone system and the cardiac natriuretic peptides. Heart. 1996;76:36-44.
- Maisel A, Mueller C, Adams K Jr, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008;10:824-39.
- Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension. 2007;49:241-8.
- van der Meer P, Gaggin HK, Dec W. ACC/AHA versus ESC guidelines on heart failure. JACC. 2019;73:2756-68.
- Triposkiadis F, Butler J, Abboud FM, et al. The continuous heart failure spectrum: moving beyond an ejection fraction classification. Eur Heart J. 2019;40:2155-63.
- Varzideh F, Kansakar U, Donkor K, Wilson S, Jankauskas SS, Mone P, Wang X, Lombardi A, Santulli G. Cardiac Remodeling After Myocardial Infarction: Functional Contribution of MicroRNAs to Inflammation and Fibrosis. Front. Cardiovasc. Med. 2022;9:863238.
- Nagaraju CK, Dries E, Popovic N, Singh AA, Haemers P, Roderick HL, Claus P, Sipido KR, Driesen RB. Global Fibroblast Activation throughout the Left Ventricle but Localized Fibrosis after Myocardial Infarction. Sci. Rep. 2017;7:10801.
- Grosman-Rimon L, Billia F,Wright E, Carasso S, Elbaz-Greener G, Kachel E, Rao V, Cherney D. Neurohormones, inflammatory mediators, and cardiovascular injury in the setting of heart failure. Heart Fail. Rev. 2020;25:685-701.
- Ge Z, Li A, McNamara J, Dos Remedios C, Lal S. Pathogenesis and pathophysiology of heart failure with reduced ejection fraction: Translation to human studies. Heart Fail. Rev. 2019;24:743-758.
- Nägele MP, Barthelmes J, Kreysing L, Haider T, Ruschitzka F, Sudano I, Flammer AJ. Endocrine hormone imbalance in heart failure with reduced ejection fraction: A cross-sectional study. Health Sci. Rep. 2022;5:e880.
- Albaghdadi M, Gheorghiade M, Pitt B. Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes. Eur Heart.J. 2011;32(21):2626-2633.
- Manolis AS, Manolis TA, Manolis AA, Melita H. Neprilysin Inhibitors: Filling a Gap in Heart Failure Management, Albeit Amidst Controversy and at a Significant Cost. Am. J. Cardiovasc. Drugs. 2019;19:21-36.
- Leite M, Sampaio F, Saraiva FA, Diaz SO, Barros AS, Fontes-Carvalho R. The impact of heart failure therapy in patients with mildly reduced ejection fraction: A network meta-analysis. ESC Heart Fail. 2023;10:1822-1834.
- Urbach J, Goldsmith SR. Vasopressin antagonism in heart failure: A review of the hemodynamic studies and major clinical trials. Ther. Adv. Cardiovasc. Dis. 2021;15:17539447-20977741.
- Carabello BA. Concentric versus eccentric remodeling. J. Card. Fail. 2002;8:S258-S263.
- Dobrescu M, Dumitrache C. Sisteme endocrine în cardiologie. 2012, Ed. Național.